natgillin/translations-raw huggingface dataset:
Methadon1 5 mg, enkeltdosis 500 mg hver 12. time, ↓ 36% ↓ 38% En øget methadondosis kan være nødvendig, når methadon indgives sammen med ritonavir doseret som et antiretroviralt stof eller som en farmakokinetisk forstærker på grund af induktion af glukuronidering.
Methadone1 5, single dose 500 q12h, ↓ 36% ↓ 38% Increased methadone dose may be necessary when concomitantly administered with ritonavir dosed as an antiretroviral agent or as a pharmacokinetic enhancer due to induction of glucuronidation.
Methadon:
Rash
Methadon: AUC: ↔
AUC: ↔
Methadon: AUC: ↔
Methadone: AUC: ↔
Methadon: CL/F  22 %
Methadone: CL/F 22
Methadonbehandlede patienter, som skal begynde Viramune behandling, bør monitoreres for abstinenssymp- tomer og efterfølgende have methadondosis justeret afhængigt af disse.
withdrawal and methadone dose should be adjusted accordingly.
methadondosis ved samtidig
necessary when concomitantly
methadone (aktiv) AUC  47% S-methadon Cmax  65% methadon AUC  103%
methadone (active) Cmax  31% R-methadone (active) AUC  47% S-methadone Cmax  65% methadone AUC  103
Methadons AUC kan falde ved samtidig administration af nelfinavir.
Co- administration of nelfinavir with omeprazole may lead to a loss of
Methicillin-følsomme stafylokokker herunder Staphylococcus aureus* Streptococcus agalactiae*
Methicillin-susceptible-staphylococci (including Staphylococcus aureus)* Streptococcus agalactiae
Methicillin-resistente stafylokokker +#
Methicillin-resistant staphylococci +#
Methionin dannes naturligt ud fra proteinerne i kosten og nedbrydes normalt til homocystein, derefter til cystein.
Methionine naturally comes from proteins in foods and is usually broken down into homocysteine, then cysteine.
Methionin Natriumchlorid
Methionine Sodium chloride
Methionin Polysorbat 20
Methionine Polysorbate 20
Methionin Polysorbat 20 Benzylalkohol Benzalkoniumchlorid
Methionine Polysorbate 20 Benzyl alcohol
methionin, natriumchlorid, vand til injektionsvæsker, saltsyre og natriumhydroxid
methionine, sodium chloride, water for injections, hydrochloric acid and sodium hydroxide.
methionin, natriumchlorid, vand til injektionsvæsker, saltsyre og natriumhydroxid.
methionine, sodium chloride, water for injections, hydrochloric acid and sodium hydroxide.
Methotrexat (20 mg/m2/uge, p.o.): dag 8, 15, 22
Methotrexate (20 mg/m2/week, PO): days 8, 15, 22
Methotrexat (20 mg/m²/uge, p.o.): dag 1, 8, 15, 22, 29, 36, 43, 50
Methotrexate (20 mg/m2/week, PO): days 1, 8, 15, 22, 29, 36, 43, 50
Methotrexat (20 mg/m²/uge, p.o.): dag 8, 15, 22
Methotrexate (20 mg/m2/week, PO): days 8, 15, 22
Methotrexat (5 g/m2 over 24 timer, i.v.): dag 1
Methotrexate (5 g/m2 over 24 hours, IV): day 1
Methotrexat (5 g/m2 over 24 timer, i.v.): dag 1
MTX (5 g/m2 over 24 hours, IV): day 1
Methotrexat (5 g/m2 over 24 timer, i.v.): dag 1 og 15
Methotrexate (5 g/m2 over 24 hours, IV): days 1 and 15
Methotrexat (5 g/m² over 24 timer, i.v.): dag 1
Methotrexate (5 g/m2 over 24 hours, IV): day 1
Methotrexat (5 g/m² over 24 timer, i.v.): dag 1
MTX (5 g/m2 over 24 hours, IV): day 1
Methotrexat (5 g/m² over 24 timer, i.v.): dag 1 og 15
Methotrexate (5 g/m2 over 24 hours, IV): days 1 and 15
Methotrexat (anvendes til behandling af cancer og gigtlidelser)
Methotrexate (used to treat cancer and rheumatic disorders)
methotrexat (anvendes ved behandling af bl.a. leddegigt (reumatoid artrit))
methotrexate (used to treat e.g. rheumatoid arthritis)
Methotrexat (BCRP-, OAT1-, OAT3- substrat)
Methotrexate (BCRP, OAT1, OAT3
Methotrexat (n = 228)
Enbrel + Methotrexate
methotrexat (til behandling af kræft eller leddegigt)
methotrexate (used to treat cancer or rheumatoid arthritis)
Methotrexat er kontraindiceret under graviditet (se pkt.
Methotrexate is contraindicated during pregnancy (see section 4.3).
Methotrexat forårsager desuden embryotoksicitet, abort og føtale defekter hos mennesker.
In addition, methotrexate causes embryotoxicity, abortion and foetal defects in humans.
METHOTREXAT HOS PATIENTER MED RA AF < 3 ÅRS VARIGHED
Methotrexate in Patients with RA of <3 Years Duration
METHOTREXAT HOS PATIENTER MED RA AF<3 ÅRS VARIGHED
Methotrexate in Patients with RA of <3 Years Duration
METHOTREXAT HOS PATIENTER MED REUMATOID ARTRIT AF < 3 ÅRS VARIGHED
Methotrexate in Patients with RA of <3 Years Duration
METHOTREXAT HOS PATIENTER MED REUMATOID ARTRIT AF<3 ÅRS VARIGHED
Methotrexate in Patients with RA of <3 Years Duration
Methotrexat kan forårsage medfødte misdannelser, skade det ufødte barn eller medføre abort, og det er derfor meget vigtigt, at det ikke bruges af gravide patienter eller patienter, der planlægger at blive gravide.
Methotrexate can cause birth defects, harm unborn babies or cause miscarriages, and so it is very important that it is not given to pregnant patients or patients planning to become pregnant.
Methotrexat og cytarabin kan påvirke virkningen på en anden måde, da tidligere administration af disse stoffer kan øge Oncaspars virkning gennem en synergistisk effekt.
Methotrexate and cytarabine can interfere differently: prior administration of these substances can increase the action of Oncaspar synergistically.
Methotrexat påvirker produktionen af sæd og æg midlertidigt.
Methotrexate temporarily affects sperm and egg production.
Methotrexat påvirker spermatogenesen og oogenesen i den periode, hvor det administreres, hvilket kan medføre nedsat fertilitet.
Methotrexate affects spermatogenesis and oogenesis during the period of its administration which may result in decreased fertility.
METHOTREXAT vs.
Methotrexate vs.
Methotrexat – anvendes mod leddegigt og kræft
Methotrexate – used for rheumatoid arthritis and cancer
methotrexat,
methotrexate,
methotrexat, et lægemiddel der anvendes til at behandle alvorlige ledsygdomme (reumatoid artrit) eller hudsygdomme (psoriasis).
methotrexate, a medicine used to treat severe joint disease (rheumatoid arthritis) or skin disease (psoriasis),
methotrexat, et lægemiddel, der typisk bruges til at behandle kræft
methotrexate, a medicine typically used to treat cancer
Methotrexat-naive
Methotrexate-Naive
Methotrexat:
ubstrate)
methotrexat: et lægemiddel til behandling af rheumatoid arthritis, cancer og hudsygdommen psoriasis
methotrexate: a medicine to treat rheumatoid arthritis, cancer and the skin disease, psoriasis
methotrexat: et lægemiddel, der bruges til at behandle svær inflammation af led (gigt), kræft og hudsygdommen psoriasis
methotrexate: a medicine to treat severe joint inflammation (rheumatoid arthritis), cancer and the skin disease psoriasis.
Methotrexate (n = 258 perioder)
Methotrexate (n = 258 cycles)
methoxypolyethylenglycol-epoetin beta
methoxy polyethylene glycol-epoetin beta
methyldopa (anvendes til behandling af forhøjet blodtryk), apomorphin (anvendes til behandling af Parkinsons sygdom),
alpha-methyldopa (used to treat increased blood pressure), apomorphine (used for Parkinson’s disease),
Methyldopa Der har været isolerede rapporter om hæmolytisk anæmi, som er opstået ved samtidig brug af hydrochlorthiazid og methyldopa.
Methyldopa There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.
methylergonovin)
methylergonovine)
Methylnaltrexonbromid bør ikke anvendes under graviditet, medmindre det er klart nødvendigt.
Methylnaltrexone should not be used during pregnancy unless clearly necessary.
Methylnaltrexonbromid fremstilles af naltrexon, som er et velkendt stof, der anvendes til at modvirke virkningen af opioider.
Methylnaltrexone bromide is derived from naltrexone, a well-known substance that is used to block the action of opioids.
Methylnaltrexonbromid påvirker i mindre gradevnen til at føre motorkøretøj ogbetjene maskiner.
Methylnaltrexone bromide has minor influence on the ability to drive and use machines.
Methylnaltrexonbromid skal anvendes med forsigtighed til patienter med læsioner, eller hos hvem der er mistanke om læsioner i mave-tarm-kanalen.
Methylnaltrexone bromide should be used with caution in patients with known or suspected lesions of the GI tract.
Methylparahydroxybenzoat (0,125%) Kaliumdihydrogenphosphat Dinatriumhydrogenphosphatdihydrat Carbomer (carbopol 974 PNF) Natriumhydroxid opløsning
Methyl parahydroxybenzoate (0.125%) Potassium dihydrogen phophate Disodium hydrogen phosphate dihydrate Carbomer (carbopol 974 PNF)
Methylparahydroxybenzoat (E 218) 1,6 mg
Methyl parahydroxybenzoate (E 218) 1.6 mg
Methylparahydroxybenzoat (E 218) 2,0 mg
Methyl parahydroxybenzoate (E 218) 2.0 mg
Methylparahydroxybenzoat (E 218), og propylparahydroxybenzoat (E 216) kan medføre allergiske reaktioner (muligvis forsinkede).
Methyl parahydroxybenzoate (E 218), and propyl parahydroxybenzoate (E 216) may cause allergic reactions (possibly delayed).
Methylparahydroxybenzoat (E218) 1,5 mg/ml Propylparahydroxybenzoat (E216) 0,2 mg/ml
Methyl parahydroxybenzoate (E218) 1.5 mg/ml Propyl parahydroxybenzoate (E216) 0.2 mg/ml
Methylparahydroxybenzoat (E218) og propylparahydroxybenzoat (E 216) kan medføre allergiske reaktioner (muligvis forsinkede).
Methyl parahydroxybenzoate (E 218), and propyl parahydroxybenzoate (E 216), may cause allergic reactions (possibly delayed).
Methylparahydroxybenzoat (E218) Propylparahydroxybenzoat (E216) Natriumdihydrogenphosphat, vandfri Dinatriumphosphat, vandfri (E339) Sucralose (E955)
Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Sodium dihydrogen phosphate, anhydrous Disodium phosphate, anhydrous (E339) Sucralose (E955)
Methylparahydroxybenzoat (E218) Propylparahydroxybenzoat (E216) Propylenglycol (E1520) Maltodextrin
Methyl parahydroxybenzoate (E218) Propyl parahydroxybenzoate (E216) Propylene glycol (E1520) Maltodextrin
Methylparahydroxybenzoat  0,8 mg/ml.
Methyl parahydroxybenzoate  0.8 mg/ml.
methylparahydroxybenzoat, der kan give allergiske reaktioner (kan optræde efter behandlingen).
Methylparahydroxybenzoate which may cause allergic reactions (possibly delayed).
Methylphenidat
Methylphenidate
methylphenidat (anvendes til at behandle hyperaktivitet hos børn og narkolepsi (overdreven søvnighed))
methylphenidate (used to treat hyperactivity in children and narcolepsy (excessive sleepiness))
Methylprednisolon 40 mg intrathecal, dag 1
Methylprednisolone 40 mg intrathecal, day 1
Methylthioniniumchlorid
Methylthioninium chloride
Methylthioniniumchlorid bør undgås hos patienter, som modtager lægemidler, der forstærker serotonerg transmission, herunder selektive serotoningenoptagelseshæmmere (SSRI), bupropion, buspiron, clomipramin, mirtazapin og venlafaxin.
Methylthioninium chloride should be avoided in patients receiving medicinal products that enhance serotonergic transmission including SSRIs (selective serotonin reuptake inhibitors), bupropion, buspirone, clomipramine, mirtazapine, and venlafaxine.
Methylthioniniumchlorid Proveblue 5 mg/ml injektionsvæske, opløsning
Methylthioninium chloride Proveblue 5 mg/ml solution for injection
Methylthioniniumchlorid Proveblue 5 mg/ml injektionsvæske, opløsning methylthioniniumchlorid
Methylthioninium chloride Proveblue 5 mg/ml injection methylthioninium chloride
Methylthioniniumchlorid Proveblue 5 mg/ml injektionsvæske, opløsning. methylthioniniumchlorid
Methylthioninium chloride Proveblue 5 mg/ml solution for injection methylthioninium chloride
Methylthioniniumchlorid Proveblue anvendes til voksne og børn i alle aldre som modgift til behandling af symptomer på methæmoglobinæmi forårsaget af eksponering for lægemidler eller kemikalier.
Methylthioninium chloride Proveblue is used in adults and children of all ages as an antidote to treat symptoms of methaemoglobinaemia caused by exposure to medicines or chemicals.
Methylthioniniumchlorid Proveblue er en injektionsvæske, opløsning, der indeholder det aktive stof methylthioniniumchlorid (5 mg/ml).
Methylthioninium chloride Proveblue is a solution for injection that contains the active substance methylthioninium chloride (5 mg/ml).
Methylthioniniumchlorid Proveblue er hypotonisk og kan fortyndes i 50 ml glukose 50 mg/ml (5 %) injektionsvæske, opløsning for at undgå lokale smerter, navnlig hos den pædiatriske population.
Methylthioninium chloride Proveblue is hypotonic and may be diluted in 50 ml glucose 50 mg/ml (5%) solution for injection to avoid local pain, in particular in paediatric population.
Methylthioniniumchlorid Proveblue et "hybridt generisk lægemiddel".
Methylthioninium chloride Proveblue is a ‘hybrid generic medicine’.
Methylthioniniumchlorid Proveblue injiceres langsomt i en vene over et tidsrum på fem minutter.
Methylthioninium chloride Proveblue is injected slowly into a vein over a period of five minutes.
Methæmoglobinæmi er en lidelse, hvor blodet indeholder for meget af en unormal form af hæmoglobin, der ikke kan transportere ilt effektivt.
Methaemoglobinaemia is a condition where there is too much of an abnormal form of haemoglobin in the blood that is not able to transport oxygen effectively.
methæmoglobinæmi fremkaldt af chloratforgiftning
methaemoglobinaemia caused by chlorate poisoning,
methæmoglobinæmi fremkaldt af nitrit under behandling af cyanidforgiftning
methaemoglobinaemia caused by nitrite during treatment of cyanide poisoning,
Metoclopramid
UMetoclopramideU
metoclopramid – anvendes til behandling af kvalme og opkastning, navnlig hos patienter med migræne glyceryltrinitrat (GTN, nitroglycerin), isosorbidmononitrat, erythrityltetranitrat,
Metoclopramide – used to treat feelings of sickness (nausea) and vomiting, including in patients with migraine
Metode og måden at give medicinen på
Method and route of administration
Metode til vurderingen (f.eks.
Method used for assessment (e.g.
Metode- og brugerfejl: 0,38 (øvre grænse 95 % konfidensinterval 0,97)
Method and user failure: 0.38 (upper limit 95 % confidence interval 0.97)
Metode- og brugerfejl: 1,16 (øvre grænse 95 % konfidensinterval 2,08)
Method and user failure: 1.16 (upper limit 95 % confidence interval 2.08)
Metodefejl: 0,40 (øvre grænse 95 % konfidensinterval 1,03)
Method failure: 0.40 (upper limit 95 % confidence interval 1.03)
Metodefejl: 1,22 (øvre grænse 95 % konfidensinterval 2,18)
Method failure: 1.22 (upper limit 95 % confidence interval 2.18)
Metoden for indsamling af information om brug af Odomzo og overholdelse af graviditetsprogrammet og dets effektivitet som en del af lægemiddelovervågning
Methodology to collect information on the use of Odomzo and the compliance with the pregnancy pharmacovigilance programme and its effectiveness
Metoden til at estimere nyrefunktionen (CrCl i ml/min) i løbet af den kliniske udvikling af Lixiana var Cockcroft-Gault-metoden.
The method used to estimate renal function (CrCL in mL/min) during the clinical development of Lixiana was the Cockcroft-Gault method.
Metoden til forberedelse af NexoBrid og til applikation på sårområdet
The method of preparation of NexoBrid and of its application to wound area
Metoden, der blev anvendt til at estimere nyrefunktionen (CrCL i ml/min) under den kliniske udvikling af Pradaxa, var Cockcroft-Gault-metoden.
The method used to estimate renal function (CrCL in mL/min) during the clinical development of Pradaxa was the Cockcroft-Gault method.
Metoderne til at mindske interferensen omfatter behandling af reagens-erytrocytter med dithiothreitol (DTT) for at bryde bindingen af daratumumab eller andre lokalt validerede metoder.
The interference mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to disrupt daratumumab binding or other locally validated methods.
Metoprolol (anvendt ved hjertesvigt)
Dihydroergotamine
Metoprolol (anvendt ved hjertesvigt)
ergonovine, ergotamine or
metoprolol (medicin til behandling af hjertesvigt)
metoprolol (used to treat heart failure)
metoprolol – bruges til at sænke blodtrykket og/eller mindske hjertefrekvensen
metoprolol – used to lower blood pressure and/or reduce heart rate
metronidazol (medicin mod infektioner)
metronidazole (used to treat infections)
metropolol (mod hjertesygdomme)
metoprolol (for heart disorders)
metroragi, menoragi
metrorrhagia, menorrhagia
metroragi, menoragi, brystsmerter, bækkensmerter
metrorrhagia, menorrhagia, breast pain, pelvic pain
Metrorragi
Metrorrhagia
Metrorragi Ovariecyster
Vaginal haemorrhage
MF (EU)- nummer
MA (EU)  number
MF (EU)- nummer
MA (EU) Number
MF (EU)-number
MA (EU) number
mg breve
mg sachets
mg emodepsid, 15 mg praziquantel
mg emodepside, 15 mg praziquantel.
mg indgivet
mg. administered
mg kapsel Gelatine
50 mg Capsule shell Gelatin
mg pakning:
4 mg pack:
mg per kg = mg for hvert kilogram af barnets vægt.
mg per kg = mg for each kilogram of the infant’s body weight.
mg sammen med efavirenz
with efavirenz could be
mg selamectin appliceret
mg of selamectin dispensed
mg svarer til 5 dråber.
mg corresponding to 5 drops.
mg teduglutid-pulver i et hætteglas (glas) med gummiprop (brombutyl).
mg teduglutide powder in vial (glass) with rubber stopper (bromobutyl).
mg to gange dagligt)
twice daily)
mg to gange dagligt, og
increased to 400 mg twice daily
mg to gange dagligt/100 mg to gange
darunavir/ritonavir 600/100 mg
mg to gange dagligt/100 mg to gange
Fosamprenavir/ritonavir/Efavirenz (700 mg twice daily/100 mg twice daily/600 mg once daily)
mg uden ritonavir (n=28).
without ritonavir (n=28).
mg én gang dagligt om aftenen
daily in the evening without
mg/100 mg 2 gange daglig
400mg/100 mg BID
mg/dag
2000 mg/day
mg/dag
mg/day
mg/kg (interval)
mg/kg range
mg/kg givet som en intravenøs infusion efterfulgt af yderligere infusionsdoser på 5 mg/kg 2 og uger efter den første infusion, herefter hver 6. til 8. uge.
mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and weeks after the first infusion, then every 6 to 8 weeks.
mg/kg givet som en intravenøs infusion efterfulgt af yderligere infusionsdoser på 5 mg/kg 2 og uger efter den første infusion, herefter hver 8. uge.
5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.
mg/kg kropsvægt pr. dag
mg/kg body weight dose per day
mg/m² legemsoverflade pr. dag
mg/m² body surface area dose per day
MGIT® (Mycobacterium growth indicator tube liquid media system) n= forsøgspersoner med SCC ved 2 måneder
MGIT® Mycobacterium growth indicator tube liquid media system n= subjects with SCC at 2 months
MI (tavst MI undtaget)b
MI (excl. silent MI)b
MI i alt inkluderer tavst MI, -dato for hændelsen er sat til dato for konstatering. d Nominel signifikansværdi; alle andre er formelt statistisk signifikante ifølge prædefinerede hierarkiske tests.
Total MI includes silent MI, with date of event set to date when discovered. dNominal significance value; all others are formally statistically significant by pre-defined hierarchical testing.
MI i alt inkluderer tavst MI, -dato for hændelsen er sat til dato for opdagelse. d Nominel signifikansværdi; alle andre er formelt statistisk signifikante ifølge prædefinerede hierarkiske tests.
Total MI includes silent MI, with date of event set to date when discovered. dNominal significance value; all others are formally statistically significant by pre-defined hierarchical testing.
MI kunne også rapporteres efter bedømmelse fra den blindede sikkerhedskomité af en investigator- rapport.
MI could also be reported following CEC adjudication of an investigator report.
MI uden
Common:
MI uden
haematoma
Mibefradil eller diltiazem, medicin som bruges til behandling af forhøjet blodtryk og kronisk angina pectoris.
Mibefradil or diltiazem, medicines to treat hypertension and chronic angina pectoris.
MIC (interval) (µg/ml)
MIC (Range) (µg/ml)
MIC af vild-type population (µg/ml)
MIC of wild-type population(µg/ml)
MIC værdier for ibafloxacin (modersubstans) i området 0,032 – 0,5 g/ml ses hos isolater fra hund af E. coli, Staphylococcus spp., Proteus mirabilis, stammer af Pasteurella spp. og Salmonella spp.
For ibafloxacin (parent compound), MIC values ranging from 0.032 – 0.5 µg/ml are observed for canine isolates of E. coli, Staphylococcus spp., Proteus mirabilis, strains of Pasteurella spp. and Salmonella spp.
MIC- koncentrationer for retapamulin i S. aureus-isolater med laboratoriefremkaldte mutationer i ribosomal protein L3 var 0,25-4 µg/ml.
For S. aureus isolates with laboratory- generated mutations in ribosomal protein L3, retapamulin MICs were 0.25-4 µg/ml.
MIC-breakpoint (mg/l)
MIC breakpoint (mg/L)
MIC-værdier for Salmonella blev angivet at være i området 4-16 µg/ml, og alle stammer var vild-typer.
MIC values for Salmonella were reported to be in the range of 4–16 µg/ml, and all strains were wild type.
MIC-værdier for Salmonella blev angivet til at være i området 4-16 µg/ml, og alle stammer var vildtyper.
MIC values for Salmonella were reported to be in the range of 4-16 µg/ml, and all strains were wild type.
MIC50(µg/ml)
MIC50 (µg/ml)
MIC90 (µg/ml)
Actinobacillus pleuropneumoniae (n=50)
MIC90(µg/ml)
MIC90 (µg/ml)
Micafungin gives intravenøst.
Micafungin is an intravenously administered medication.
Micafungin hæmmer ikke-kompetitivt syntesen af 1,3--D-glucan, der er en essentiel komponent i svampens cellevæg.
Micafungin non-competitively inhibits the synthesis of 1,3--D-glucan, an essential component of the fungal cell wall.
Micafungin var ikke mutagent eller klastogent i et arsenal af standardundersøgelser omfattende både in vitro og in vivo tests, herunder et in vitro-studie ”Unscheduled DNA Synthesis” med hepatocytter fra rotter.
Micafungin was not mutagenic or clastogenic when evaluated in a standard battery of in vitro and in vivo tests, including an in vitro study on unscheduled DNA synthesis using rat hepatocytes.
Micafunginbehandling bør først gives efter nøje vurdering af risk/benefit- forholdet, især af patienter med svært nedsat leverfunktion eller kroniske leversygdomme med præneoplastiske tilstande, som f.eks. fremskreden leverfibrose, cirrose, viral hepatit, neonatal leversygdom eller medfødte enzymdefekter eller hos patienter, som samtidig får behandling, som har hepatotoksiske og/eller genotoksiske egenskaber.
Micafungin treatment should be conducted on a careful risk/benefit basis, particularly in patients having severe liver function impairment or chronic liver diseases known to represent preneoplastic conditions, such as advanced liver fibrosis, cirrhosis, viral hepatitis, neonatal liver disease or congenital enzyme defects, or receiving a concomitant therapy including hepatotoxic and/or genotoxic properties.
Micardis 20 mg er pakket i blisterpakninger med 14, 28, 56, eller 98 tabletter.
Micardis is available in blister packs containing 14, 28, 56, or 98 tablets.
Micardis 20 mg tabletter er hvide runde tabletter, hvorpå firmaets logo og koden 50H er præget.
Micardis 20 mg tablets are white, round and engraved with the code number '50H' on one side and the company logo on the other side.
Micardis 20 mg tabletter telmisartan
Micardis 20 mg tablets telmisartan
Micardis 40 mg tabletter er hvide aflange tabletter, hvorpå firmaets logo og koden 51H er præget.
Micardis 40 mg tablets are white, oblong-shaped, and engraved with the code number '51H' on one side and the company logo on the other side.
Micardis 40 mg tabletter telmisartan
Micardis 40 mg tablets telmisartan
Micardis 80 mg tabletter er hvide aflange tabletter, hvorpå firmaets logo og koden 52H er præget.
Micardis 80 mg tablets are white, oblong-shaped and engraved with the code number '52H' on one side and the company logo on the other side.
Micardis 80 mg tabletter telmisartan
Micardis 80 mg tablets telmisartan
Micardis bruges til behandling af essentiel hypertension (forhøjet blodtryk) hos voksne. ’Essentiel’ betyder, at der ikke er nogen anden sygdom, der er årsag til, at blodtrykket er forhøjet.
Micardis is used to treat essential hypertension (high blood pressure) in adults. ‘Essential’ means that the high blood pressure is not caused by any other condition.
Micardis kan også ordineres i kombination med diuretika (vanddrivende medicin) såsom hydrochlorthiazid, der har vist sig at øge den blodtryksnedsættende virkning af Micardis.
Alternatively, Micardis may be used in combination with diuretics ('water tablets') such as hydrochlorothiazide which has been shown to have an additive blood pressure lowering effect with Micardis.
MicardisPlus 40 mg /12,5 mg tabletter telmisartan/hydrochlorthiazid
MicardisPlus 40 mg/12.5 mg tablets telmisartan/hydrochlorothiazide